CCKBR and neoplasm: Consistent with these findings, our data indicate that [177Lu]Lu-DOTA-CCK2R-dimer can effectively reduce therapy-resistant tumor subpopulations, such as C4, suggesting the potential for improved therapeutic outcomes in aggressive malignancies.